| Events Column |
|
|
| 10/14
MIT Enterprise Forum of CT more |
|
|
10/21
3:30 pm - 6:00 pm
CURE/Yale BioHaven Entrepreneurship Series: Cara Therapeutics.
Anlyan Center, Yale Medical School, New Haven. Watch for
details.
|
|
|
|
11/11
MIT Enterprise Forum of CT more
|
|
|
11/18
3:30 pm - 6:00 pm
CURE/Yale BioHaven Entrepreneurship Series: Helix
Therapeutics. Anlyan Center, Yale Medical School, New Haven.
Watch for details.
|
|
|
|
2/10
MIT Enterprise Forum of CT more
|
|
|
|
3/10
MIT Enterprise Forum of CT more
|
|
|
|
4/7
MIT Enterprise Forum of CT more
|
|
|
|
5/5
MIT Enterprise Forum of CT more
|
|
|
|
|
An
All-Important Summer
From the desk of Paul
Pescatello, President and CEO of CURE
 Now that summer is in full swing, the stakes for Connecticut’s biopharma industry couldn’t be greater.
Our state faces a nearly $9 billion deficit. Many proposals have been floated to close this gap, including elimination of some or all of Connecticut’s incentives for biopharma research and development. Suffice it to say, CURE’s working in every way possible to make clear how tremendously counterproductive such proposals are.
For the full story |
|
|
CURE
Op-Eds Support Biologics Reform Bill
Two recent op-eds by Paul Pescatello, president and CEO
of CURE, support the Pathway for Biosimilars Act, a bill now
before the U.S. House of Representatives (HR 1548):
Norwich Bulletin
July 13 and New
Haven Register
July 16.
Pescatello urges Congress, as it weights reforming the
health care system, to do so in a way that fosters
development of biologics, which are increasingly being seen
as the key to treating such serious illnesses as
Alzheimer's, diabetes, and cancer.
For the
full story
|
|
|
Curagen Acquired by Celldex Therapeutics
CuraGen Corporation, the Branford-based biotech, has agreed to be acquired for $95 million by Celldex Therapeutics, Inc. of Needham, MA in a tax-free stock-for-stock transaction.
Companies and operations that emerged from CuraGen are still active in the state, a testament to its contribution to Connecticut bioscience, Paul
Pescatello, president and CEO of CURE, told the
Hartford Courant.
For the
full story
|
|
|
Affomix
Presents at CURE/Yale BioHaven Series
 Rounding out the 2008-2009 CURE/Yale BioHaven Entrepreneurship seminar series was a presentation
May 6 by Affomix Corporation, a development-stage company based in Branford, CT.
The
company has proprietary technology for rapid, automated, high-throughput selection of human monoclonal antibodies.
For the
full story |
|
|
CURE Member News Digest
 454
Life Sciences collaborates on hemorrhagic fever sequencing
Achillion in discussions with
Gilead on licensing
Alexion wins Prix Galien France
award
Applied Spine names Craig Corrance
CEO
Bayer HealthCare announces cancer
therapy results
Boehringer Ingelheim announces
oral antidiabetic compounds
Bristol-Myers Squibb presents
diabetes results
CuraGen to be acquired by Celldex
Danbury Hospital physicians on
"Top Docs" list
GlaxoSmithKline gears up for flu
pandemic
Dr. Martin Wand of Hartford Hospital
gets ophthalmology post
Johnson
& Johnson reports rheumatoid arthritis results
ManKind announces
next-generation inhalation system
Neurogen considers
strategic options
Pfizer to
launch program for uninsured
PhRMA
champions
free-market initiatives
Protein Sciences gets
$35 million contract from HHS
Purdue
Pharma announces
RYZOLT™ extended-release tablets
Quinnipiac
University named to "best universities"
list
Rib-X
names Grieg to Board
Vion
presents Onrigin® poster
Wiggin and Dana
partner Carlson to head NYIPLA
Robert Birge of UConn wins 2009
Connecticut Medal of Science
Yale team makes proteasome
discoveries
For
the full story |
|
